Peptide Registry

Vials

Capsules

Liquids

a capsule of BPC-157 / TB-500 (Tβ4) Blend - 500mcg/500mcg

BPC-157/TB-500 Blend (Capsules)

$129.00

  • Contents: BPC-157 / TB-500 Blend (BPC-157 Arginate Salt 500mcg / Thymosin Beta-4 fragment 500mcg)
  • Format: Encapsulated solid
  • Appearance: White to off-white solid
  • Purity: >99%
Quantity Discount Price
1 - 3 - $129.00
4 - 7 10% $116.10
8 + 18% $105.78
SKU: N/A Category: Brand:

Description

This blend combines BPC-157 Arginate Salt and TB-500 (Thymosin Beta-4 fragment; Ac-LKKTETQ) in equal 500mcg doses per capsule for oral administration research. BPC-157 operates through VEGFR2-mediated angiogenic signaling and FAK/paxillin focal adhesion pathway activation. TB-500 operates through G-actin sequestration, enabling rapid actin polymerization at cell migration leading edges and endothelial tubulogenesis. The two mechanisms are independent at the receptor level, making the BPC-157 and TB-500 capsules a tool for studying dual-pathway vascular and cytoskeletal biology through oral delivery in the same experimental model. The arginate salt BPC-157 form provides improved gastric stability appropriate for oral protocols.

Storage and Handling

Store in a cool, dry place away from heat, moisture, and direct light. Keep container tightly sealed when not in use. Refer to the lot-specific certificate of analysis for recommended storage conditions.

Compliance Notice

BPC-157/TB-500 Blend capsules are for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. This product has not been evaluated by the FDA. By purchasing this product, the buyer confirms that they will use it exclusively for controlled research.

Frequently Asked Questions

How does the capsule blend format differ from the vial blend for research?

The vial blend format is reconstituted for parenteral administration. The capsule format is designed for oral administration research. The arginate salt BPC-157 form provides improved gastric stability for the oral route. Researchers should select based on the administration route their protocol requires. Single-compound control arms remain essential for attributing effects to individual components.

Why are two mechanistically distinct compounds combined in one capsule?

BPC-157 and TB-500 address different signaling axes. Their combination in a single capsule simplifies oral administration protocols where both pathways are simultaneously active experimental variables, without the need to separately administer two compounds in the same session.

Related products